Related Experiment Video
Updated: Aug 30, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Potential New Therapeutic Approaches for Cisplatin-Resistant Testicular Germ Cell Tumors
André van Helvoort Lengert1, Leticia do Nascimento Braga Pereira1, Eduardo Ramos Martins Cabral1
1Molecular Oncology Research Center, Barretos Cancer Hospital, 14784400 Barretos, Sao Paulo, Brazil.
Background:
Testicular germ cell tumors (TGCTs), a group of heterogeneous neoplasms, are the most frequent tumors of teenagers and young men, with the incidence rising worldwide. High cure rates can be achieved through cisplatin (CDDP)-based treatment, but approximately 10% of patients present refractory disease and virtually no treatment alternatives. Here, we explored new strategies to treat CDDP-resistant.
Methods:
In vitro TGCT CDDP-resistance model was established and differential mRNA expression profiles were evaluated using NanoString technology. Then, TGCT cell lines were treated with four potential drugs (PCNA-I1, ML323, T2AA, and MG-132) to overcome CDDP-resistance.
Results:
We found several differentially expressed genes related to DNA repair and cell cycle regulation on CDDP-resistant cell line (NTERA-2R) compared to parental cell line (NTERA-2P), and the proteasome inhibitor MG-132 demonstrated cytotoxic activity in all cell lines evaluated, even at a nanomolar range. MG-132 also enhanced cell lines' sensitivity to CDDP, increasing apoptosis in both NTERA-2P and NTERA-2R.
Conclusions:
MG-132 emerges as a potential new drug to treat CDDP-resistant TGCT. Targeted therapy based on molecular mechanism insights may contribute to overcome acquired chemotherapy CDDP-resistance.
Insights
The proteasome inhibitor MG-132 shows promise in treating cisplatin-resistant testicular germ cell tumors (TGCTs). This drug demonstrated cytotoxic effects and enhanced sensitivity to cisplatin, offering new hope for patients with refractory disease.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Testicular germ cell tumors (TGCTs) are common in young men, with rising incidence globally.
- Cisplatin (CDDP)-based chemotherapy is effective, but 10% of patients develop resistance, lacking treatment options.
Purpose of the Study:
- To explore novel therapeutic strategies for CDDP-resistant TGCTs.
- To identify potential drugs that can overcome CDDP resistance in TGCT cell lines.
Main Methods:
- Established an in vitro model of CDDP-resistant TGCT.
- Analyzed differential mRNA expression using NanoString technology.
- Screened four drugs (PCNA-I1, ML323, T2AA, MG-132) for efficacy against CDDP-resistant TGCT.
Main Results:
- Identified differentially expressed genes in DNA repair and cell cycle regulation in resistant cells.
- The proteasome inhibitor MG-132 exhibited potent cytotoxic activity across TGCT cell lines.
- MG-132 increased sensitivity to CDDP and enhanced apoptosis in both sensitive and resistant TGCT cells.
Conclusions:
- MG-132 is a potential therapeutic agent for CDDP-resistant TGCT.
- Targeted therapies informed by molecular insights can help overcome acquired chemotherapy resistance in TGCT.
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...